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Abstract 47 
We have previously shown that impulsivity in rats is linked to decreased dopamine D2/3 receptor 48 
availability in the ventral striatum. In the present study we investigated, using longitudinal positron 49 
emission tomography (PET), the effects of orally-administered methylphenidate (MPH), a first line 50 
treatment in attention deficit hyperactivity disorder, on D2/3 receptor availability in the dorsal and ventral 51 
striatum and related these changes to impulsivity. Rats were screened for impulsive behavior on a 5-52 
choice serial reaction time task. After a baseline PET scan with the D2/3 ligand [
18
F]fallypride, rats 53 
received 6 mg/kg MPH, orally, twice each day for 28 days. Rats were then re-assessed for impulsivity 54 
and underwent a second [
18
F]fallypride PET scan. Prior to MPH treatment we found that D2/3 receptor 55 
availability was significantly decreased in the left but not right ventral striatum of high-impulsive (HI) rats 56 
compared with low-impulsive (LI) rats. MPH treatment increased impulsivity in LI rats, and modulated 57 
impulsivity and D2/3 receptor availability in the dorsal and ventral striatum of HI rats through inverse 58 
relationships with baseline levels of impulsivity and D2/3 receptor availability, respectively.  However, we 59 
found no relationship between the effects of MPH on impulsivity and D2/3 receptor availability in any of 60 
the striatal sub-regions investigated. These findings indicate that trait-like impulsivity is associated with 61 
decreased D2/3 receptor availability in the left ventral striatum, and that stimulant drugs modulate 62 
impulsivity and striatal D2/3 receptor availability through independent mechanisms. 63 
 64 
 65 
 66 
 67 
 68 
 69 
 70 
 71 
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Introduction 72 
Converging evidence from neuroimaging, clinical psychopharmacology and animal models implicates 73 
dysregulated dopaminergic and norepinephrinergic neurotransmission in the pathophysiology of 74 
attention deficit hyperactivity disorder (ADHD), the prototypical impulse-control disorder (Biederman, 75 
2005; Arnsten, 2006; Dalley et al., 2011). Methylphenidate (MPH), which acts by increasing extra-76 
synaptic dopamine (DA) and norepinephrine (NE) levels by blocking their reuptake (Zetterstrom et al., 77 
1988), has been the first-line pharmaceutical therapy for ADHD (Wilens, 2008). Although its 78 
pharmacological action has been well characterized, the precise neurobiological mechanisms 79 
underlying the therapeutic effects of MPH remain unclear. Recent findings suggest that only 80 
specific neurocognitive processes in domains such as impulse control and attention are 81 
affected by MPH, and that these interact with the drug in a baseline performance-dependent 82 
manner (Dews and Wenger, 1977; Sahakian and Robbins, 1977; Robbins and Sahakian, 1979; 83 
Turner et al., 2003; Clatworthy et al., 2009; DeVito et al., 2009). Such effects are hypothesized to 84 
follow an inverted U-shaped function, which depend on optimising catecholamine levels in the 85 
brain (Clatworthy et al., 2009; van der Schaaf et al., 2013).  86 
 Recently, we reported a similar baseline dependent effect of cocaine in a preclinical 87 
animal model of impulsivity (Caprioli et al., 2013).  We reported that impaired response inhibition in 88 
a rodent model of impulsivity is associated with a deficiency in DA D2/3 receptor availability in the left 89 
ventral striatum, and that prior response-contingent exposure to cocaine both restored D2/3 receptor 90 
availability in this region and improved impulse control. This evidence directly supports the baseline 91 
dependency hypothesis at the neurobiological level in the striatum and this may be relevant to recent 92 
findings observed by Volkow and colleagues. Indeed, a set of well-powered case-control positron 93 
emission tomography (PET) studies in adult medication-naïve ADHD patients, found ADHD to be 94 
associated with reduced D2/3 receptor availability in the nucleus accumbens and caudate (Volkow et 95 
al., 2007b; Volkow et al., 2007a; Volkow et al., 2009), and that treatment response was associated with 96 
increased DA transmission in the ventral striatum (Volkow et al., 2012). Thus, the clinical efficacy of 97 
stimulant drugs such as MPH in ADHD may depend, in part, on restoring D2/3 receptor signalling in the 98 
ventral striatum of impulsive individuals. 99 
In the present study we therefore investigated the effects of repeated oral administration of MPH 100 
on D2/3 receptor availability in the ventral striatum of high-impulsive rats on the 5-choice serial reaction 101 
time task (5-CSRTT). Impulsivity in this task is measured by the number of anticipatory responses to 102 
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an imminent visual signal and is analogous to false alarms on the analogous continuous performance 103 
test in humans (Robbins, 2002). We used PET and the selective high-affinity D2/3 receptor antagonist 104 
[
18
F]fallypride (Mukherjee et al., 1995) to investigate D2/3 receptor availability in the ventral and dorsal 105 
striatum, both prior to, and following chronic exposure of rats to MPH. In parallel, we investigated the 106 
relationship between behavioral impulsivity in selected low (LI)- vs high (HI)-impulsive rats and MPH-107 
evoked changes in D2/3 receptor availability in the ventral and dorsal striatum. 108 
Material and Methods 109 
Subjects 110 
Ninety-six adult male Lister-hooded rats (Charles River, Margate, UK), weighing 250-275 g and 2-3 111 
months of age at the beginning of behavioral training, were used. These were housed in groups of four 112 
in enclosed ventilation chambers during the initial training and selection of HI and LI rats. Upon 113 
completion of the screening and for the remaining period of the study rats were singly housed (n=8 HI; 114 
n=7 LI), similar to our previous study (Caprioli et al., 2013). Rats were singly housed because 115 
MPH has been shown to disrupt social behavior in adolescent and young adult rats (Beatty et 116 
al., 1982; Arakawa, 1994; Vanderschuren et al., 2008). The holding room was humidity- and 117 
temperature-controlled (22C), and rats were maintained under a reversed 12-h light/dark cycle (white 118 
lights off/red lights on at 07:00 h). Food was restricted to maintain body weights at 85-90% of free-119 
feeding weights. Water was available ad libitum. The present experiment conformed to the UK Animals 120 
(Scientific Procedures) Act of 1986 and local ethical guidelines. A timeline of experimental procedures 121 
is shown in Figure 1. 122 
Five-choice serial reaction time task 123 
The 5-CSRTT apparatus has been described in detail elsewhere (Bari et al., 2008). The training 124 
procedure used in the present study was identical to that previously described (Caprioli et al., 2013). In 125 
brief, rats were trained on the 5-CSRTT over approximately 60 daily sessions (6 sessions per week) to 126 
detect the location of a brief visual stimulus (0.7 s) presented on a random basis in one of the five 127 
recesses. Each session consisted of 100 discrete trials and lasted approximately 30 min. Training was 128 
considered complete when rats’ responded to the target stimuli of duration 0.7 s with an accuracy of 129 
75% and omissions on fewer than 20% of trials. Trials were initiated by subjects entering the 130 
magazine. After a fixed inter-trial interval (ITI) of 5 s, a visual stimulus was presented in a single 131 
aperture. Rats were rewarded with a single pellet if they correctly located the position of the target 132 
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stimulus (a ‘correct’ response). A failure to respond within a limited hold period of 5 s was deemed an 133 
‘omission’ and was signalled by a 5 s time-out period and a loss of food reward on that trial. Similar 134 
feedback was given on trials where rats responded in an adjacent aperture (an ‘incorrect’ response) or 135 
prior to the onset of the light stimulus (a ‘premature’ response). Behavioral performance was assessed 136 
by choice accuracy (% correct responses/ (correct + incorrect trials); premature responding: (% 137 
premature responses/ (correct + incorrect + omission trials); omissions (% omission trials/ (correct + 138 
incorrect + omission trials); latency to collect food (time from nose-poke response to entering the 139 
magazine, ms); correct response latency (time to make a response in the correct aperture after the 140 
onset of the light stimulus). Once rats had acquired the 5-CSRTT they were ranked for impulsivity 141 
during a 3-week screening period. Each week consisted of five consecutive days of testing with 142 
days 1, 2, 4 and 5 comprising sessions each of 100 discrete trials and an ITI of 5 s (short ITI). 143 
During day 3, the ITI was increased to 7s to increase the frequency of premature responses 144 
(long ITI). HI animals were defined as those exhibiting a level of premature responding greater 145 
than 50 on all three L-ITI sessions. LI rats were selected from the remaining rats and responded 146 
prematurely on fewer than 30% of trials during the L-ITI sessions. 147 
 148 
Chronic methylphenidate treatment 149 
Methylphenidate hydrochloride (Sigma, Cambridge, UK) was dissolved in Ribena (GlaxoSmithKline, 150 
UK) and administered orally (6 mg/ml/kg) twice a day (10:00 and 17:00). The oral route of 151 
administration was used to model the normal manner in which this drug is administered clinically 152 
(Kuczenski and Segal, 2002; Swanson and Volkow, 2009). Two days prior to the first oral dosing of 153 
MPH, rats were trained to consume the Ribena solution from a 1 ml syringe. Chronic MPH exposure 154 
was maintained for 7 days a week for 4 consecutive weeks (see Figure 1). During this period, rats 155 
were assessed for performance on the 5-CSRTT at 08:00 when rats were in the drug-free state (i.e., 156 
15 hours after the last MPH administration). During the last 7 days of MPH treatment, rats were 157 
challenged with three L-ITI sessions, each spaced 3 days apart. 158 
 159 
Analysis of methylphenidate and ritalinic acid 160 
Four non-impulsive rats were used to quantify plasma levels of MPH and its metabolite ritalinic acid. 161 
Rats were orally administered Ribena spiked with 6 mg/kg MPH, as described above, and after 10 min 162 
were anesthetized with 5% isoflurane. General anaesthesia was maintained via the delivery of 1.5% 163 
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isoflurane in medical air. Blood samples were taken from a tail vein (0.5 ml) at 5, 15, 30, 60, 90 and 164 
120 minutes following MPH administration. Blood was allowed to clot at room temperature (24°C) 165 
before being centrifuged at 2000 rpm for 10 min. Plasma was aspirated from the centrifuged sample 166 
and stored at -80° C prior to the determination of MPH and ritalinic acid using HPLC-MS/MS. 167 
Calibration standards (range 0.01-5 mg/L) were prepared with MPH and ritalinic spiked in blank rat 168 
plasma. Quality control samples were similarly prepared at 0.05, 1.00 and 1.50 mg/L. Calibration 169 
standards and triplicate controls were carried through with each batch of analysis. Samples were 170 
prepared by adding 50 µL of test specimen, calibrators or controls to 2 mL of 100 mM phosphate buffer 171 
(pH 6.0) and spiking with the internal standard (10 µL of 20% acetonitrile in 0.1% aqueous formic acid 172 
containing 100 pg d
3
-MPH). The solutions were then placed in an ultrasonic bath for 10 minutes before 173 
extracting the drugs by adding to a pre-conditioned Strata Screen-C GF 200mg/6 mL SPE column. 174 
Ritalinic acid was eluted first with hexane/ethyl acetate (50:50) followed by MPH using 175 
dichloromethane/isopropanol/ammonia (78:20:2). The eluates were evaporated to dryness at 30
o
C and 176 
reconstituted in 100 µL of methanol/water prior to injection into an HPLC-MS/MS for analysis. HPLC 177 
separation was achieved using a FORTIS 3µm C18 150 x 3 mm column with detection using API 3200 178 
MS/MS with a TurboIon spray interface. The HPLC consisted of a Shimadzu system with mobile phase 179 
A consisting of water containing 0.01% ammonia and mobile phase B consisting of methanol 180 
containing 0.01% ammonia with 10 mL of isopropanol added per litre. The gradient run was 20%-100% 181 
mobile phase B over 10 minutes. Positive MRM was used to monitor the chromatography column 182 
eluent [MPH (MRM 234-84), ritalinic acid (MRM 220-84) and d3-MPH (MRM 237-84)]. The LLOD was 183 
0.008 mg/L (S/N ratio 10) and the LLOQ was 0.01 mg/L. The overall precision (between batch quality 184 
control specimens run on 4 separate days) was 2-11% within the calibration range employed. 185 
Positron emission tomography 186 
HI and LI rats were scanned using [
18
F]fallypride PET on two occasions; prior to the first oral MPH 187 
dose and 2 days after the last MPH dose, which occurred within 48 h of the last L-ITI session on the 5-188 
CSRTT (see Figure 1). The scanning procedure has been described in detail elsewhere (Caprioli et al., 189 
2013). In brief, prior to the injection of tracer, singles-mode transmission data were acquired using a 190 
rotating 
68
Ge/
68
Ga point source (~20 MBq) to provide measured attenuation correction. For all scans, 191 
[
18
F]fallypride was injected intravenously over 30 s, followed by a 15 s heparin-saline flush. The 192 
injected [
18
F]fallypride activity (5.3–66.9 MBq) was adjusted so that the total mass of labelled and 193 
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unlabelled fallypride injected was 0.5 nmol/kg. Dynamic data were acquired in list-mode for 180 min 194 
and subsequently binned into sinograms for the following time frames: 6  10 s, 3  20 s, 6  30 s, 10  195 
60 s, 10  120 s, 29  300 s. Corrections were applied for randoms, dead time, normalization, 196 
attenuation and decay. Fourier re-binning (Defrise et al., 1997) was used to compress the 4D 197 
sinograms to 3D prior to reconstruction with 2D filtered back projection with a Hann window cut-off at 198 
the Nyquist frequency. The image voxel size was 0.95 x 0.95 x 0.80 mm, with an array size of 128  199 
128  95. The reconstructed images were converted to kBq/ml using global and slice factors 200 
determined from imaging a uniform phantom filled with a [
18
F]fluoride solution. 201 
Thirty-two T2-weighted MR brain scans from previous [
18
F]fallypride PET studies in Lister-hooded 202 
rats were used to create a high resolution MR brain template with SyN (Avants et al., 2008), part of the 203 
Advanced Normalization Tools (ANTS) package. A PET template was then created by applying the 204 
spatial normalisation parameters from the above template creation process to late [
18
F]fallypride 205 
images (average image 120-180 min after injection) that had been manually co-registered to their 206 
corresponding MR scan. Late [
18
F]fallypride images from the 30 PET scans in this study were affine 207 
registered to the PET template using ANTS and each transformation was used to re-slice the 208 
corresponding dynamic [
18
F]fallypride PET image set to template space. Finally, the MR template used 209 
in a previous study (Caprioli et al., 2013)(see Figure 2A) was spatially normalised to the new MR 210 
template described above, with the resulting transformation applied to the previously defined regions of 211 
interest to align them to the new template space. 212 
D2/3 receptor availability was quantified using non-displaceable binding potential (BPND) (Innis et 213 
al., 2007), determined from reference tissue-based kinetic analysis with the cerebellum acting as the 214 
reference region. The borders of the reference region drawn on the MR template excluded the 215 
outermost lamina of the cerebellar cortex in order to avoid partial volume error from uptake in the 216 
Purkinje cell layer. Regional and voxel-wise BPND were estimated from the distribution volume ratio 217 
(DVR; BPND = DVR - 1) determined using the reference tissue input Logan plot (Logan et al., 1996) 218 
with data fitted from 90 to 180 min post-injection. 219 
Statistical analysis 220 
Behavioral data were subjected to analysis of variance (SPSS, version 17.0, Chicago, USA) using a 221 
general linear model. Homogeneity of variance was verified using Levene's test. For repeated-222 
measures analyses, Mauchly's test of sphericity was applied and the degrees of freedom corrected to 223 
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more conservative values using the Huynh-Feldt epsilon for any terms involving factors in which the 224 
sphericity assumption was violated. Differences in BPND between HI and LI rats were evaluated using 225 
repeated measures ANOVA. Significantly meaningful interactions (p<0.1) were further analyzed by 226 
simple main effects using the pooled sum of square error term (Cochran and Cox, 1957). A 227 
significance level of α = 0.05 was used to interpret main effects and post-hoc tests. Pearson product 228 
moment correlations were used to assess the strength of the association between: (i) the 229 
change in BPND ((post-MPH−pre-MPH)/(pre-MPH) × 100) and baseline BPND (pre-MPH scan); (ii) 230 
the change in premature responses ((post-MPH−pre-MPH)/(pre-MPH) × 100) and baseline BPND 231 
(pre-MPH scan). All figures show group means ± 1SEM. 232 
 233 
Results 234 
Segregation of high and low impulsivity groups 235 
The behavioral performance of LI and HI rats on the 5-CSRTT is summarized in Table 1. Percentage 236 
premature responses for HI (n=8) and LI (n=7) rats, averaged across the three L-ITI sessions prior to 237 
the commencement of MPH dosing, were 69.6 ± 7.5% (mean ± SEM) and 21.5 ± 2.2%, respectively. 238 
HI rats were more impulsive than LI rats regardless of the ITI being set to 5 s (‘b1’ to ‘b10’, ‘S-ITI’ 239 
p=0.002) or 7 s (‘L-ITI’ p<0.001). Among the various behavioral variables recorded only attentional 240 
accuracy was significantly impaired in HI rats compared with LI rats during the L-ITI sessions 241 
(p=0.014). Although omissions appeared to be increased in HI rats compared with LI rats this 242 
contrast was not significant (p=0.054). 243 
Interactive effects of methylphenidate on impulsivity in LI and HI rats 244 
Twenty one days after the commencement of daily MPH dosing, rats were re-assessed for impulsivity 245 
and attentional performance on the 5-CSRTT. It can be seen in Figure 1B that MPH produced 246 
divergent effects on impulsivity in the two impulsivity sub-groups with impulsivity appearing to decrease 247 
in HI rats but increase in LI rats (group × MPH interaction: F(1,13)=7.59, p=0.016). Although post-hoc 248 
t-tests failed to reveal a significant decrease in impulsivity, at a group level, following MPH treatment in 249 
HI rats (p=0.095), the increase in impulsivity observed in LI rats was significant (p=0.044). Thus, 250 
following exposure to MPH, the initial contrast in impulsivity between LI and HI rats was greatly 251 
diminished. Importantly, it can be seen in Figure 1C that MPH increased impulsivity in LI rats in an 252 
inverse relationship to the baseline level of impulsivity, while impulsivity decreased in HI rats, with the 253 
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magnitude of the decrease being positively correlated to the baseline level of impulsivity. Thus, the 254 
effect of MPH to increase impulsivity was greatest in LI rats showing the lowest baseline level of 255 
impulsivity (r = -0.80; p=0.03) whereas MPH decreased impulsivity to a greater extent in those HI rats 256 
showing the highest baseline level of impulsivity (r = -0.7; p=0.05). However, MPH did not restore the 257 
attentional inaccuracy of HI rats, which remained significantly impaired relative to LI rats (main effect of 258 
group F(1,13) = 3.62, p=0.049; group x MPH interaction: F(1,13) = 0.37, p=0.55). Moreover there were no 259 
significant effects of MPH on omissions or magazine latencies on the 5-CSRTT (Figure 1D and Table 260 
1). 261 
Modulation of D2/3 receptor availability in the ventral striatum by MPH 262 
Consistent with our recent study (Caprioli et al., 2013), the availability of D2/3 receptors was significantly 263 
reduced in the left (t(13) = 2.25, p=0.043) but not the right (t(13) = 1.29, p=0.219) ventral striatum of drug-264 
naïve HI rats compared with LI rats (pre-/post-MPH  x hemisphere x group interaction: F(1,13)=5.75, 265 
p=0.05; group × hemisphere interaction: F(1,13)=4.047, p=0.066, Figure 2C). Following 28 days of 266 
exposure to MPH, the difference in D2/3 receptor availability between LI and HI rats in the left ventral 267 
striatum was no longer evident (t(13) = 0.09, p=0.930). The normalizing effect of MPH on D2/3 receptor 268 
availability in the left ventral striatum appeared to be explained by a near-significant reduction in D2/3 269 
BPND in the LI group (t(6) = 2.292, p=0.062) rather than an increase in D2/3 BPND in this region of HI rats 270 
(t(7) = -0.495, p=0.636). Exposure of LI and HI rats to MPH had no significant effect on D2/3 receptor 271 
availability in the right ventral striatum. 272 
Baseline-dependent effects of MPH on striatal D2/3 receptors in high impulsive rats 273 
We found no significant group differences in D2/3 receptor availability between LI and HI rats in the 274 
dorsal striatum, either at baseline (pre-MPH) or following MPH treatment (data not shown). However, 275 
when we compared the change in [
18
F]fallypride BPND before and after drug we found that MPH both 276 
increased and decreased [
18
F]fallypride BPND in the ventral and dorsal striatum in HI rats depending on 277 
the baseline availability of D2/3 receptors (Figure 3). In the ventral striatum we observed a strong 278 
inverse relationship between the percentage change in [
18
F]fallypride BPND and baseline [
18
F]fallypride 279 
BPND in both the left (rleft = -0.73, p <0.01) and right (rright= -0.58, p <0.01) hemisphere. Baseline-280 
dependent effects of MPH on D2/3 receptor availability were also observed in the anterior and posterior 281 
dorsal striatum of HI rats. For all regions of interest the relationship was strongly inversely related to 282 
baseline D2/3 receptor availability (anterior dorsal striatum HI rats: rleft = -0.74, <0.01; rright=-0.64, p 283 
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<0.01; posterior dorsal striatum HI rats: rleft =-0.61, p <0.01, rright=-0.72, p <0.01). In contrast, we did not 284 
observe baseline dependent effects on D2/3 receptor availability in any of the striatal areas investigated 285 
in LI rats. 286 
We next compared the relative changes in D2/3 receptor availability and impulsivity produced by 287 
MPH treatment (Figure 4). We found no significant relationship between these parameters in any of the 288 
striatal sub-regions examined for either LI rats or HI rats. 289 
Discussion 290 
This study investigated striatal D2/3 receptor availability in highly impulsive rats and the mechanisms 291 
underlying the therapeutic effects of chronic oral MPH. We found that repeated oral MPH was sufficient 292 
to produce bi-directional effects on impulsivity that depended on the baseline level of impulsivity. Thus, 293 
in LI rats, MPH increased impulsivity whereas in HI rats it reduced impulsivity in animals exhibiting the 294 
highest baseline level of impulsivity, consistent with an underlying rate dependent mechanism. Our 295 
results indicate that the rate dependency model held for LI and HI rats but with clear differences in the 296 
underlying regulatory parameters suggestive of a non-unitary process. Since the baseline dependent 297 
effects of MPH on impulsivity and D2/3 receptors were dissociable we conclude that D2/3 receptors may 298 
not play a major contribution to the effects of MPH on impulsivity. These data are consistent with 299 
findings showing that MPH modulates performance in humans in a baseline-dependent manner 300 
both in healthy controls and in subjects diagnosed with ADHD (del Campo et al., 2013).  301 
We found a strong inverse relationship between baseline D2/3 BPND and the change in this 302 
parameter after MPH treatment in HI rats. However no such relationship was found for LI rats in any of 303 
the striatal sub-regions examined. These findings correspond with our earlier findings in rats self-304 
administering cocaine, which had the similar effect of modulating D2/3 BPND in a manner dependent on 305 
baseline D2/3 BPND (Caprioli et al., 2013). However, in our previous study, cocaine also modulated D2/3 306 
receptors in the dorsal striatum. The more pervasive effects of cocaine on D2/3 receptors 307 
throughout the ventral and dorsal striatum may be due to differences in the route of 308 
administration (intravenous vs oral), response-contingent cocaine vs response non-contingent 309 
MPH, differing quantities of cocaine and MPH, and higher relative efficacy of cocaine over MPH. 310 
This may explain why cocaine produced a more substantial reduction in impulsivity in the HI sub-group 311 
compared with MPH in the present study (Caprioli et al., 2013).  312 
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The mechanism underling the observed rate dependent modulation of impulsivity following MPH 313 
treatment is unknown but as discussed above may be distinct for LI and HI rats. Although for LI rats 314 
there was no obvious relationship between baseline D2/3 BPND and the change in this parameter 315 
following MPH treatment, at a group level, MPH had the trend effect of reducing D2/3 BPND in the left 316 
ventral striatum, a deficit associated with increased impulsivity on this task (Dalley et al., 2007) and 317 
localized to the nucleus accumbens shell (Besson et al., 2010; Jupp et al., 2013). The reduction in D2/3 318 
receptor availability in LI rats may reflect a down-regulation of D2/3 receptors but since [
18
F]fallypride 319 
competes with DA in binding to D2/3 receptors it could also reflect an increase in synaptic DA release, 320 
possibly due to sensitization of the mesolimbic DA systems following repeated MPH treatment 321 
(Shuster et al., 1982; Gaytan et al., 1997). However, sensitization of the locomotion response does not 322 
appear to develop after chronic oral MPH treatment (McNamara et al., 1993; Kuczenski and Segal, 323 
2002). Furthermore, no simple relationship exists between hyperactivity and impulsivity on the 5-324 
CSRTT (Dalley et al., 2007; Molander et al., 2011; Moreno et al., 2013). 325 
In HI rats MPH had the dual effect of decreasing impulsivity and modulating striatal D2/3 receptor 326 
availability according to the principal of rate dependency (Dews and Wenger, 1977). However, neither 327 
parameter significantly co-varied after MPH treatment suggesting that the modifying effects of MPH on 328 
impulsivity are separable from effects on D2/3 receptor regulation. That the measure of impulsivity is not 329 
directly related to changes in D2/3 receptor availability is possibly due to other actions of MPH, 330 
especially for example on NE. Thus, atomoxetine, which reduces impulsivity in HI rats, blocks re-331 
uptake of NE and has no effect on subcortical DA (Bymaster et al., 2002). Moreover, this drug exerts at 332 
least some of its anti-impulsive effects within the shell region of the nucleus accumbens (Economidou 333 
et al., 2012). Alternatively, the reduction in impulsivity in MPH-treated HI rats may include actions at 334 
the level of the nucleus accumbens core. Thus, previously, we have shown that HI rats exhibit a 335 
reduced density of markers associated with dendritic spines in this region and GABA synthesis 336 
(Caprioli et al., 2014), abnormalities that were mainly restricted to the left hemisphere similar to the 337 
locus of deficient D2/3 receptor availability in HI rats (Caprioli et al., 2013). Since in the present study 338 
MPH had the greatest beneficial effects in the most impulsive animals these effects may be mediated 339 
by a restoration of the structural and functional integrity of GABA-ergic medium spiny neurons in the 340 
nucleus accumbens core, as previously hypothesized (Caprioli et al., 2014). The origin of the 341 
hemispheric imbalance in D2/3 receptors in HI rats is unknown but may arise from genetic 342 
and/or environmental factors affecting trophic signalling during development (Concha et al., 343 
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2012). Left/right asymmetries in the midbrain DA systems have been reported in rats (Carlson 344 
and Glick, 1989; Afonso et al., 1993; Rodriguez et al., 1994) and healthy humans (Tomer et al., 345 
2008), as well as ADHD (del Campo et al., 2013; Volkow et al., 2007a; Volkow et al., 2009). 346 
An analogous PET study in rats found that treating rats with oral MPH for 8 months, initiated during 347 
the peri-adolescent period, increased D2/3 availability in the striatum (Thanos et al., 2007). By contrast, 348 
striatal D2/3 availability decreased 2 months after starting MPH treatment. These findings demonstrate 349 
the MPH-induced changes in striatal D2/3 receptors depend on treatment length and developmental 350 
stage (Rodriguez et al., 2010; Gill et al., 2012). The mechanisms underlying these changes in D2/3 351 
receptors are unknown but may involve alterations in synaptic DA and/or the pool of receptors 352 
available for binding in the striatum. However, research in non-human primates, demonstrates that 353 
chronic treatment with extended-release MPH for 1 year has no effect on the DA transporter or D2/3 354 
receptors in the striatum (Gill et al., 2012; Soto et al., 2012). This discrepancy with rodent studies may 355 
be species-specific or a consequence of differing doses of MPH and/or length of treatment. In the 356 
context of the present study it may also reflect the fact that animals in the Gill study were not pre-357 
selected for impulsivity-related traits. This may be relevant as it has been shown that treating adults 358 
with ADHD for 1 year decreases striatal D2/3 receptor availability, as assessed using PET (Volkow et 359 
al., 2012). 360 
There are several limitations of the present study that merit discussion. Firstly, although we dosed 361 
MPH orally and assessed serum MPH levels and its metabolite ritalinic acid, as endorsed by others 362 
(Volkow and Insel, 2003; Gill et al., 2012), peak MPH levels were in excess of the typical therapeutic 363 
range of MPH of 8 to 10 ng/ml (Swanson and Volkow, 2002) (Table 2). However, consistent with other 364 
research (Patrick et al., 1984; Robb et al., 2014), MPH was rapidly cleared with an elimination half-life 365 
of 30-50 minutes. Thus, although serum levels of MPH were initially high these soon declined to 366 
clinically-relevant values after the administration of MPH and well before the next dose. Nevertheless, 367 
with twice daily dosing and consequent fluctuations in serum MPH our results are difficult to 368 
extrapolate to studies in humans that use extended-release oral formulations (Robb et al., 2014). A 369 
second consideration is that the primary objective of our research was to investigate the long term 370 
effects of MPH on impulse control and D2/3 receptors in the striatum. The design of our study thus 371 
excluded the analysis of acute, low doses of MPH, which increase NE and DA availability selectively in 372 
the prefrontal cortex (Berridge et al., 2006) and facilitate cognitive functions relevant to ADHD 373 
(Andrzejewski et al., 2014). Thirdly, our conclusions are based on relatively small group sizes 374 
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(n=7-8). Nevertheless, we have now reported in three independent studies reduced striatal D2/3 375 
receptor availability in the ventral striatum of HI rats. In addition, we observed qualitatively 376 
similar changes from baseline following administration of MPH and cocaine (Caprioli et al., 377 
2013), using a within-subjects longitudinal design.  378 
In conclusion our results confirm that deficits in impulsive control are associated with reduced D2/3 379 
receptor availability in the left ventral striatum as previously reported (Dalley et al., 2007; Caprioli et al., 380 
2013) and in three independent studies in ADHD patients (Volkow et al., 2007a; Volkow et al., 2009; 381 
del Campo et al., 2013). Although further research is needed to test the full dose-response curve of 382 
MPH on impulsivity and D2/3 receptor availability, we have now shown how different psychomotor 383 
stimulant drugs produce baseline-dependent effects on D2/3 receptor availability in the ventral striatum. 384 
In addition, we have demonstrated that the therapeutic effects of MPH on impulsivity are unlikely to 385 
arise as a direct consequence of changes in the regulation of D2/3 receptors in the ventral striatum, a 386 
conclusion supported by research in adults with ADHD (Volkow et al., 2012). Nevertheless, by 387 
restoring levels of D2/3 receptors in the ventral striatum of HI rats, MPH may diminish the risk of 388 
addiction in addiction-prone highly-impulsive rats (Belin et al., 2008; Economidou et al., 2009).  389 
 390 
391 
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Figure legends 392 
Figure 1. Effects of methylphenidate on sustained attention and impulsivity in selected low- 393 
versus high-impulsive rats. (A) Timeline of the experimental procedure in rats expressing differential 394 
levels of impulsive behavior on the 5-choice serial reaction time task (5-CSRTT). The dashed line 395 
refers to 5-CSRTT training, which took approximately 3 months. Values shown are weeks. (B) Effects 396 
of prior MPH oral administration on impulsivity in LI (white bars) and HI (black bars) rats on the 5-397 
CSRTT. Pre-cocaine values are averaged across three weekly-spaced long ITI sessions. It can 398 
be seen in Figure 1B that impulsivity was altered both in HI and LI rats (group × MPH 399 
interaction: F(1,13)=7.59, 
† 
p<0.05) during the challenge sessions. The increase in impulsivity 400 
post-MPH was significant in LI rats (
#
p=0.044). (C) Correlation plots showing the relationship 401 
between relative changes in impulsivity from baseline produced by MPH. It can be seen in 402 
Figure 1C that the effect of MPH to increase impulsivity was greatest in LI rats showing the 403 
lowest baseline level of impulsivity (r = -0.80; p=0.03) whereas MPH decreased impulsivity to a 404 
greater extent in those HI rats showing the highest baseline level of impulsivity (r = -0.7; 405 
p=0.05). (D) Differences in accuracy, omissions and magazine latency before and after the oral 406 
MPH dosing between HI and LI rats (*p<0.05, **p<0.01, ***p <0.001 HI vs LI). 407 
Figure 2. MPH-induced effects on D2/3 receptor availability in the left ventral striatum of HI and 408 
LI rats. (A) 3D depiction of regions of interest showing the ventral striatum (blue), anterior dorsal 409 
striatum (green), and posterior dorsal striatum (red). (B) Horizontal section through [
18
F]fallypride BPND 410 
maps for HI and LI rats overlaid on the co-registered MR template (L = left; R = right). The images are 411 
7 mm below the dorsal brain surface and have a BPND threshold = 8. (C) [
18
F]fallypride BPND in the left 412 
and right ventral striatum of LI (circle symbols, n=7) and HI (square symbols, n=8) rats before (‘pre-413 
MPH’) and after (‘post-MPH’) oral-administration. It can be seen that [
18
F]fallypride BPND is significantly 414 
reduced in the left ventral striatum of HI rats compared with LI rats prior to MPH exposure (* p < 0.05) 415 
and that MPH reduces the contrast in D2/3 receptor availability between LI and HI rats in the left ventral 416 
striatum. 417 
Figure 3. Relationship between the percentage change in [
18
F]fallypride BPND in the ventral and 418 
dorsal striatum before and after the exposure of LI ( panel A) and HI (panel B) rats to MPH as a 419 
function of baseline (i.e. pre-MPH) [
18
F]fallypride BPND. The results show that the effects of MPH on 420 
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D2/3 receptor availability depend inversely on baseline [
18
F]fallypride BPND in the anterior and posterior 421 
regions of the dorsal striatum, as well as in the ventral striatum of HI but not LI rats. The horizontal 422 
dotted line depicts no net effect of MPH on [
18
F]fallypride BPND. Pearson product moment correlation 423 
coefficients and p-values are given in each panel.   424 
Figure 4. Correlation plots showing the relationship between relative changes in impulsivity 425 
and [
18
F]fallypride BPND in the ventral and dorsal striatum of LI (panel A) and HI (panel B) rats 426 
produced by MPH. The results indicate that the effects of MPH on impulsivity and D2/3 receptor 427 
availability are independent. The vertical dotted line depicts no net effect of MPH on [
18
F]fallypride 428 
BPND. Pearson product moment correlation coefficients and p-values are given in each panel.   429 
430 
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Tables 628 
Table 1 629 
Summary of the effects of oral MPH administration on the behavioral performance of LI and HI rats on 630 
the 5-CSRTT. Shown are (mean ± SEM): % premature responses, % accuracy of responding, % 631 
omissions, magazine latencies (ms), and correct response latencies (ms) before (‘Pre’) and after 632 
(‘Post’) drug exposure. * p<0.05; ** p<0.01; *** p<0.001 (LI vs HI). 633 
 634 
 Pre-MPH Post-MPH 
Short-ITI sessions LI (n=7) HI (n=8) LI (n=7) HI (n=8) 
 
% premature 
 
2.9±0.5 
 
8.6±1.2** 
 
2.7±0.6 
 
4.4±0.7 
% accuracy 83.0±1.7 80.4±1.7 83.4±1.0 79.8±2.0 
% omissions 12.5±2.2 9.0±1.4 7.5±1.1 6.7±1.2 
magazine lat. (ms) 1169.4±91.9 1156.4±58.4 1213.8±85.5 1159.5±51.2 
correct lat. (ms) 751.6±38.0 626.0±41.8 842.4±50.9 688.1±40.0 
 
Long-ITI sessions 
    
 
% premature 
 
21.5±2.2 
 
69.6±7.5*** 
 
32.1±2.9 
 
53.3±4.6** 
% accuracy 80.9±1.0 73.9±2.1* 80.5±1.7 74.9±1.9* 
% omissions 12.7±1.9 18.7±2.6 8.6±1.7 11.3±2.0 
magazine lat. (ms) 1103.9±54.0 1281.9±122.7 1186.6±96.7 1140.1±49.0 
correct lat. (ms) 671.7±38.6 601.6±32.5 721.8±63.2 603.0±26.0 
 635 
 636 
Table 2  637 
Summary of the serum concentration (ng/ml) of oral methylphenidate (MPH) and ritalinic acid (RA) 638 
obtained from 4 non-impulsive rats after a single oral dose of MPH (6 mg/kg).   639 
 640 
Collection time Mean 
MPH        RA 
   SD 
MPH        RA 
Min 
MPH        RA 
     Max 
MPH        RA 
5 
15 
112.5        107.5 
102.5        142.5 
  20.6          42.7 
  22.2          20.6 
90.0          60.0 
90.0        120.0 
130.0        160.0 
130.0        170.0 
30 
60 
90 
120 
  87.5        145.0 
    9.5          67.5 
    2.2          35.0 
    1.0          13.0 
  22.2          20.8 
  7.50          15.0 
  0.91          5.78 
  0.11          8.71 
70.0        120.0 
  4.0          50.0 
  1.0          30.0 
  1.0            2.0 
120.0        170.0 
  20.0          80.0 
    3.0          40.0 
    1.0          20.0 
 641 
